Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia
详细信息 查看全文
- 作者：Kevin C. Maki ; PhD ; FNLAa ; kevin.maki@mxns.com" class="auth_mail" title="E-mail the corresponding author ; kmaki@mc-mcr.com" class="auth_mail" title="E-mail the corresponding author ; John R. Guyton ; MD ; FNLAb ; Carl E. Orringer ; MD ; FNLAc ; Ian Hamilton-Craig ; MBBS ; PhDd ; Dominik D. Alexander ; PhD ; MSPHe ; Michael H. Davidson ; MD ; FNLAf ; 1
- 关键词：Cardiovascular disease ; Cardiovascular events ; Fibrates ; Hypertriglyceridemia ; Lipid-altering drug therapy ; Niacin ; Omega-3 fatty acids ; Triglyceride-lowering therapy
- 刊名：Journal of Clinical Lipidology
- 出版年：2016
- 出版时间：July-August 2016
- 年：2016
- 卷：10
- 期：4
- 页码：905-914
- 全文大小：613 K
文摘
- class="listitem" id="list_ulist0010">
- class="label">•
Prior trials show mixed results on CVD event reduction with TG-lowering therapies.
- class="label">•
This meta-analysis evaluated CVD event risk in those with elevated TG ± low HDL-C.
- class="label">•
TG-lowering therapies reduced CVD events in subjects with elevated TG ± low HDL-C.